×
About 2,159 results

ALLMedicine™ Autoimmune Hemolytic Anemia Center

Research & Reviews  1,059 results

Graves' Disease Presenting as Autoimmune Hemolytic Anemia.
https://doi.org/10.12659/AJCR.930705
The American Journal of Case Reports; Kandinata SG, Soelistijo SA et. al.

May 4th, 2021 - BACKGROUND Atypical manifestations of Graves' disease (GD) such as anemia have been noticed in the last decades. Anemia is present in up to 34% of patients with GD, yielding various anemia types such as GD anemia, pernicious anemia, iron deficienc...

Reticulocyte Hemoglobin Equivalent in Patients with Idiopathic Warm Autoimmune Hemolyti...
https://www.ncbi.nlm.nih.gov/pubmed/33941561
Annals of Clinical and Laboratory Science; Higuchi T, Hoshi T et. al.

May 4th, 2021 - Patients with warm autoimmune hemolytic anemia (WAIHA) present with anemia that is highly heterogeneous, and often have macrocytic anemia with inappropriately elevated mean corpuscular volume (MCV). The goal of this retrospectivecase study is to e...

Iron-driven alterations on red blood cell-derived microvesicles amplify coagulation dur...
https://doi.org/10.1055/a-1497-9573
Thrombosis and Haemostasis; Delvasto L, Roem D et. al.

May 3rd, 2021 - Hemolytic disorders characterized by complement-mediated intravascular hemolysis, such as autoimmune hemolytic anemia and paroxysmal nocturnal hemoglobinuria, are often complicated by life-threatening thromboembolic complications. Severe hemolytic...

Autoimmune pancytopenia after liver transplantation: A case report.
https://doi.org/10.1016/j.transci.2021.103136
Transfusion and Apheresis Science : Official Journal of T... Barros MMO, Ayoub FL et. al.

Apr 25th, 2021 - Autoimmune hemolytic anemia (AIHA), immune thrombocytopenia (ITP), and autoimmune neutropenia (AIN) are reported in the literature after liver, intestinal, heart, pancreas, and kidney transplants. We report a case of autoimmune pancytopenia (AIHA,...

Thrombosis and thrombocytopenia in antiphospholipid syndrome: their association with me...
https://doi.org/10.1016/j.thromres.2021.04.018
Thrombosis Research; Llorente-Chávez A, Martín-Nares E et. al.

Apr 25th, 2021 - To assess the mean platelet volume (MPV), platelet-to-lymphocyte ratio (PLR), the neutrophil-to-lymphocyte ratio (NLR) and the MPV-to-lymphocyte ratio, and to test them according to the clinical/serological status, shift through time and other com...

see more →

Guidelines  2 results

Apellis’ APL-2 Receives Orphan Drug Designation from the FDA for the Treatment of Autoimmune Hemolytic Anemia
http://investors.apellis.com/news-releases/news-release-details/apellis-apl-2-receives-orphan-drug-designation-fda-treatment

Feb 4th, 2019 - Apellis Pharmaceuticals Inc. (Nasdaq:APLS), a clinical-stage biopharmaceutical company focused on the development of novel therapeutic compounds to treat diseases through inhibition of the complement system, today announced that its C3 complement ...

FDA grants orphan drug designation to APL-2 for autoimmune hemolytic anemia
https://www.healio.com/hematology-oncology/hematology/news/online/%7B2785cd04-4008-4105-91cc-e82f5573ee6f%7D/fda-grants-orphan-drug-designation-to-apl-2-for-autoimmune-hemolytic-anemia

Feb 4th, 2019 - The FDA granted orphan drug designation to the C3 complement inhibitor APL-2 for the treatment of autoimmune hemolytic anemia. Autoimmune hemolytic anemia refers to both cold agglutinin disease and warm autoimmune hemolytic anemia, which affect a ...

see more →

Clinicaltrials.gov  1,063 results

Graves' Disease Presenting as Autoimmune Hemolytic Anemia.
https://doi.org/10.12659/AJCR.930705
The American Journal of Case Reports; Kandinata SG, Soelistijo SA et. al.

May 4th, 2021 - BACKGROUND Atypical manifestations of Graves' disease (GD) such as anemia have been noticed in the last decades. Anemia is present in up to 34% of patients with GD, yielding various anemia types such as GD anemia, pernicious anemia, iron deficienc...

Reticulocyte Hemoglobin Equivalent in Patients with Idiopathic Warm Autoimmune Hemolyti...
https://www.ncbi.nlm.nih.gov/pubmed/33941561
Annals of Clinical and Laboratory Science; Higuchi T, Hoshi T et. al.

May 4th, 2021 - Patients with warm autoimmune hemolytic anemia (WAIHA) present with anemia that is highly heterogeneous, and often have macrocytic anemia with inappropriately elevated mean corpuscular volume (MCV). The goal of this retrospectivecase study is to e...

Iron-driven alterations on red blood cell-derived microvesicles amplify coagulation dur...
https://doi.org/10.1055/a-1497-9573
Thrombosis and Haemostasis; Delvasto L, Roem D et. al.

May 3rd, 2021 - Hemolytic disorders characterized by complement-mediated intravascular hemolysis, such as autoimmune hemolytic anemia and paroxysmal nocturnal hemoglobinuria, are often complicated by life-threatening thromboembolic complications. Severe hemolytic...

Autoimmune pancytopenia after liver transplantation: A case report.
https://doi.org/10.1016/j.transci.2021.103136
Transfusion and Apheresis Science : Official Journal of T... Barros MMO, Ayoub FL et. al.

Apr 25th, 2021 - Autoimmune hemolytic anemia (AIHA), immune thrombocytopenia (ITP), and autoimmune neutropenia (AIN) are reported in the literature after liver, intestinal, heart, pancreas, and kidney transplants. We report a case of autoimmune pancytopenia (AIHA,...

Thrombosis and thrombocytopenia in antiphospholipid syndrome: their association with me...
https://doi.org/10.1016/j.thromres.2021.04.018
Thrombosis Research; Llorente-Chávez A, Martín-Nares E et. al.

Apr 25th, 2021 - To assess the mean platelet volume (MPV), platelet-to-lymphocyte ratio (PLR), the neutrophil-to-lymphocyte ratio (NLR) and the MPV-to-lymphocyte ratio, and to test them according to the clinical/serological status, shift through time and other com...

see more →

News  35 results

Sutimlimab boosts hemoglobin, quality of life in cold agglutinin disease
https://www.mdedge.com/hematology-oncology/article/214191/anemia/sutimlimab-boosts-hemoglobin-quality-life-cold-agglutinin?channel=39313
Neil Osterweil

Dec 12th, 2019 - ORLANDO – An investigational selective inhibitor of the complement pathway, sutimlimab, induced rapid and sustained benefits in patients with cold agglutinin disease, a rare autoimmune hemolytic anemia with no currently approved effective therapie.

Autoimmune Hemolytic Anemia: Evaluation and Diagnosis
https://www.mdedge.com/hematology-oncology/article/210264/anemia/autoimmune-hemolytic-anemia-evaluation-and-diagnosis/page/0/3?channel=182

Oct 18th, 2019 - Transfusion Therapy Performing transfusions can be very difficult in patients with AIHA. 2 The presence of the autoantibody can interfere with typing of the blood and almost always interferes with the crossmatch, since this final step consists of m.

Autoimmune Hemolytic Anemia: Treatment of Common Types
https://www.mdedge.com/hematology-oncology/article/210272/anemia/autoimmune-hemolytic-anemia-treatment-common-types/page/0/4?channel=182

Oct 18th, 2019 - Drug-Induced Hemolytic Anemia AIHA caused by a drug reaction is rare, with a lower incidence than drug-related ITP. The rate of severe drug-related AIHA is estimated at 1:1,000,000, but less severe cases may be missed.

C3 inhibitor shows potential in PNH and AIHA
https://www.mdedge.com/hematology-oncology/article/199135/anemia/c3-inhibitor-shows-potential-pnh-and-aiha?channel=39313
Will Pass

Apr 18th, 2019 - GLASGOW – APL-2, a complement factor 3 (C3) inhibitor, may be a future treatment option for paroxysmal nocturnal hemoglobinuria (PNH) and autoimmune hemolytic anemia (AIHA), according to investigators from two separate studies. Will Pass/MDedge Ne.

Apellis’ APL-2 Receives Orphan Drug Designation from the FDA for the Treatment of Autoimmune Hemolytic Anemia
http://investors.apellis.com/news-releases/news-release-details/apellis-apl-2-receives-orphan-drug-designation-fda-treatment

Feb 4th, 2019 - Apellis Pharmaceuticals Inc. (Nasdaq:APLS), a clinical-stage biopharmaceutical company focused on the development of novel therapeutic compounds to treat diseases through inhibition of the complement system, today announced that its C3 complement ...

see more →